Author of

• 36336

  +

  P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy - Clinically Focused
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36443

    +

    P76.97 - Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis (ID 3609)

    00:00 - 00:00  |  Presenting Author(s): DEZHI Cheng
    • Abstract
    • Slides

    Introduction
    

    With the development of next-generation sequencing (NGS) technology, it has facilitated the discovery of important gene fusions in lung cancer. Food and Drug Administration (FDA) has approved several inhibitors for the treatment of lung cancer patients harboring different gene fusions, such as Crizotinib, Ceritinib and Alectinib for ALK fusion+ patients, Selpercatinib for RET fusion+ patients, Entrectinib and Crizotinib for ROS1 fusion+ patients and so on. In the present study, we described the fusion landscape in a large Chinese lung cancer cohort, which offered an estimate of the proportion of patients with gene fusion who might benefit from therapies.

    Methods
    

    NGS profiling was performed on 12,888 lung cancer patients from January 2017 to November 2019, including 7401 tissue samples and 5487 plasma samples. The fusion patterns of ALK, BCR, BRAF, EGFR, NTRK1, PDGFRB, PDGFRA, RARA, RET and ROS1 genes, as well as the co-occurrence with driver mutations were analyzed.

    Results
    

    A total of 767 (5.95%) patients with gene fusion were detected, including 62% (476/767) of patients in ALK fusion, 18% (137/767) of patients in RET fusion, 12% (93/767) of patients in ROS1 fusion, 4% (32/767) of patients in BRAF fusion, 1.4% (11/767) of patients in NTRK1 fusion, 1.4% (11/767) of patients in PDGFRA fusion, 1.2% (9/767) of patients in EGFR fusion, 0.5% (4/767) of patients in PDGFRB fusion and 0.3% (2/767) of patients in BCR fusion. Compared to lung cancer patients in the original cohort (n = 12,888; 7,211 males, 5,677 females), the fusions mainly occurred in females (P<0.001, Pearson’s chi-squared test). Additionally, 8.6% (66/767) of patients were identified with co-mutated actionable variations, such as 56 patients harboring mutations in exon 18–21 of EGFR, 2 patients harboring BRAF V600E, 1 patient harboring ERBB2 exon 20 insertions, 10 patients harboring mutations in exon 2 of KRAS and 2 patients harboring MET exon 14 skipping mutations.

    Conclusion
    

    To our knowledge, this is the largest cohort to study the landscape of gene fusions in Chinese lung cancer patients. Some fusions are detected at a lower frequency than previous report, which may due to the large proportion of plasma samples. The results may offer information in more effective personalized diagnosis and therapies.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.